Global Cancer Biologics Market Size study & Forecast, by Product (Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, and Immune Checkpoint Inhibitors), by Application (Non-small Cell Lung Cancer, Prostate Cancer, Bre

Global Cancer Biologics Market Size study & Forecast, by Product (Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, and Immune Checkpoint Inhibitors), by Application (Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Others), by Distribution Channel (Hospitals, Clinics, and Others) and Regional Analysis, 2023-2030

Global Cancer Biologics Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Cancer biologics refer to a class of drugs that are designed to target specific molecules or pathways involved in the growth and spread of cancer cells. They are typically derived from living organisms, such as proteins, antibodies, and vaccines, and are designed to interact with specific targets on cancer cells. These drugs are often used in the treatment of various types of cancer and may be used alone or in combination with other treatments, such as chemotherapy, radiation therapy, or surgery. Cancer biologics may also be referred to as biologic therapies, biotherapeutics, or targeted therapies. The major driving factors for the Global Cancer Biologics Market are increasing incidences of cancer and increasing demand for targeted and personalized medicine. Moreover, technological advancements and favorable regulatory environment are creating lucrative growth opportunities in the market over the forecast period 2023-2030.

The rising incidences of cancer are one of the primary drivers of the cancer biologics market. Globally, the number of new cases of cancer was 19.3 million in 2020, according to the GLOBOCAN 2020 statistics. This number is expected to increase to 30.2 million by 2040. This significant rise in cancer cases underscores the urgent need for effective cancer treatments, including small molecule drugs, which have shown promise in the treatment of various types of cancer. However, the high cost of Cancer Biologics stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Cancer Biologics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. The North American market for cancer biologics is expected to be the largest due to the presence of major pharmaceutical companies, high healthcare expenditure, and increasing cancer prevalence. The US is expected to dominate the market due to the high adoption rate of advanced cancer treatments. The Asia-Pacific market for cancer biologics is expected to witness significant growth due to factors such as increasing cancer prevalence, improving healthcare infrastructure, and increasing investment in R&D. China and Japan are expected to be the major contributors to the market growth.

Major market players included in this report are:
Roche Holding AG
Novartis AG
Merck & Co., Inc.
Bristol-Myers Squibb Company
Amgen Inc.
Johnson & Johnson
Pfizer Inc.
AstraZeneca plc
Eli Lilly and Company
AbbVie Inc.

Recent Developments in the Market:
In January 2020, F. Hoffmann-La Roche AG announced that it had submitted a supplemental biological license application to the U.S. Food and Drug Administration (FDA) for Tecentriq (atezolizumab), in combination with the drug Avastin (bevacizumab), for the treatment of the most common form of liver cancer.

Global Cancer Biologics Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product, Application, Distribution Channel, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Monoclonal Antibodies
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Immune Checkpoint Inhibitors

By Application:
Non-small Cell Lung Cancer
Prostate Cancer
Breast Cancer
Acute Myeloid Leukemia
Lymphoma
Others

By Distribution Channel:
Hospitals
Clinics
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Roche Holding AG
Novartis AG
Merck & Co., Inc.
Bristol-Myers Squibb Company
Amgen Inc.
Johnson & Johnson
Pfizer Inc.
AstraZeneca plc
Eli Lilly and Company
AbbVie Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.